文献速递肝病

西美瑞韦联合索磷布韦治疗初治和经治的基因4型丙型肝炎病毒感染患者:一项III期、开放标签、单臂研究(PLUTO)

Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-29

PLUTO研究为III期开放标签单臂试验,评估西美瑞韦联合索磷布韦治疗12周对初治和经治的基因4型丙型肝炎病毒感染患者(伴或不伴代偿性肝硬化)的疗效和安全性。40例患者全部获得持续病毒学应答(SVR12),100%(Clopper-Pearson 95%置信区间:91-100%);不良事件均为1或2级,见于50%患者,未报告严重不良事件。

要点

  • 基因4型丙型肝炎初治和经治患者(伴或不伴代偿性肝硬化)接受西美瑞韦联合索磷布韦12周,SVR12达100%。
  • 不良事件均为1或2级,20/40(50%)患者报告;未报告严重不良事件。
  • 3级治疗中出现实验室异常见于2/40(5%)患者。

核心结论

  • 西美瑞韦联合索磷布韦治疗12周在初治和经治的基因4型丙型肝炎病毒感染患者(伴或不伴代偿性肝硬化)中SVR12率为100%,且耐受性良好。

研究设计与样本

  • III期、开放标签、单臂研究(PLUTO),40例成人慢性基因4型丙型肝炎病毒感染患者接受西美瑞韦150mg每日一次联合索磷布韦400mg每日一次治疗12周;主要疗效终点为治疗结束后12周的持续病毒学应答(SVR12),同时评估安全性。

主要发现

  • 所有患者均获得SVR12(100%,Clopper-Pearson 95%置信区间:91-100%);不良事件均为1或2级,发生在20/40(50%)患者,未报告严重不良事件,无患者中止研究治疗;3级治疗中出现实验室异常见于2/40(5%)患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and subsequent hepatocellular carcinoma. HCV genotype 4 is found widely in the Middle East, Egypt and Africa, and has also spread into Europe. There are limited data available regarding the use of direct-acting antiviral agents in HCV genotype 4-infected patients with cirrhosis. AIM: To evaluate in the phase III, open-label, single-arm PLUTO study the efficacy and safety of 12 weeks of simeprevir (HCV NS3/4A protease inhibitor) plus sofosbuvir (HCV nucleotide-analogue NS5B polymerase inhibitor) in treatment-naïve and (peg)interferon ± ribavirin-experienced HCV genotype 4-infected patients, with or without compensated cirrhosis. METHODS: Adult patients with chronic HCV genotype 4 infection received simeprevir 150 mg once-daily and sofosbuvir 400 mg once-daily for 12 weeks. The primary efficacy endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12). Safety was also assessed. RESULTS: Forty patients received treatment; the majority were male (73%) and treatment-experienced (68%). Overall, 7/40 (18%) patients had compensated cirrhosis. All patients achieved SVR12 [100% (Clopper-Pearson 95% confidence interval: 91-100%)]. Adverse events, all Grade 1 or 2, were reported in 20/40 (50%) patients. No serious adverse events were reported and no patients discontinued study treatment. Grade 3 treatment-emergent laboratory abnormalities were noted in 2/40 (5%) patients. CONCLUSIONS: Treatment with simeprevir plus sofosbuvir for 12 weeks resulted in SVR12 rates of 100% in treatment-naïve and -experienced patients with HCV genotype 4 infection with or without compensated cirrhosis, and was well tolerated. [NCT02250807].

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Buti M, Calleja JL, Lens S, et al. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther. 2016. PMID: 27896822. doi:10.1111/apt.13883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。